Allergan, Inc, makers of Botox, Latisse, lapband and breast implants, acquired the cosmetic and reconstructive surgery unit of Serica Technologies yesterday. The primary products of this Serica division, and a logical addition to Allergan’s product line, are biodegradable silk-based scaffolds for skin grafting, reconstructive surgery and breast augmentation. The transaction did not include rights to Serica's veterinary or orthopedic products, which were spun-out to a new company, Alacer Technologies, Inc.
The news came on the heels of the Monday's FDA approval of Allergan's Juvederm XC, a new version of its popular Juvederm dermal filler. Juvederm XC numbs the treatment area within seconds, reducing the need for other anesthetic.
It’s our view that this is one more example of the onrush of integration among the larger aesthetic companies.